Obesity titan could shake up Lilly and Novo after astonishing trial
The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
We can't find the internet
Attempting to reconnectSomething went wrong!
Attempting to reconnectThe San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
Medicare coverage opens the obesity pill market to millions more Americans.
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.
Today reads warmer than 2 of the last 17 scored days. Click a bar to read that day's stories.